ImmunoGen

#2508

Rank

$4.99B

Marketcap

United States

Country

Leadership team

Mr. Mark Joseph Enyedy (Pres, CEO & Director)

Ms. Susan Altschuller Ph.D. (Sr. VP & CFO)

Dr. Anna Berkenblit M.D., MM.Sc (Sr. VP & Chief Medical Officer)

Products/ Services

Biotechnology, Health Care, Medical, Therapeutics

Number of Employees

100 - 500

Headquarters

Waltham, Massachusetts, United States

Established

1981

Company Registration

SEC CIK number: 0000855654

Revenue

20M - 100M

Traded as

IMGN

Social Media

URL

https://www.immunogen.com

Overview

Location

Recognition and Award

References

Summary

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

History

ImmunoGen was founded in 1981 to create technologies that improve the potency and safety of cancer treatments and to develop related diagnostic and therapeutic products. The company is first established to be called Aclara Pharmaceuticals, for “assays that clarify.” ImmunoGen’s early ambition is to develop cancer treatments that use monoclonal antibodies to kill cancer cells. In the 1990s, the company took a pivotal step and began to develop, manufacture, and commercialize novel antibody-drug conjugates (ADCs).

Mission

Targeting a better life for people with cancer is why we get up in the morning. It’s not enough to disrupt the progress of someone’s cancer; we want to keep cancer from disrupting someone’s life.

Vision

To create more effective, better tolerated anti-cancer therapies. Specifically, they wanted to find a way to leverage the targeting ability of antibodies to deliver toxic drug directly to cancer cells. Benacerraf went on to suggest that the investors start with a grant from which the Institute would work with dedicated scientists.

Key Team

Ms. Stacy A. Coen (Sr. VP & Chief Bus. Officer)

Ms. Renee Lentini (VP of Fin. & Principal Accounting Officer)

Ms. Audrey Bergan (Sr. VP & Chief HR Officer)

Dr. Theresa G. Wingrove (Sr. VP of Regulatory Affairs & Quality)

Ms. Courtney O'Konek (Sr. Director of Corp. Communications & Investor Relations)

Mr. Daniel S. Char J.D. (Sr. VP & Chief Legal Officer)

Dr. Mary Margaret Huizinga FACP, M.D., M.P.H. (Sr. VP & Head of Medical Affairs)

Recognition and Awards

ImmunoGen has been recognized for its work in the field of cancer therapies, with numerous awards for researchers, CEOs and scientific publications. In 2011, the company was awarded the European BioPharmaceutical Association Medal in recognition of its pioneering research into antibody-drug conjugates. In 2013, ImmunoGen was also recognized with the gold medal at BIO International Convention. In 2020, ImmunoGen was named ‘Breakthrough of the Year’ in the Scrip Awards, which acknowledge scientific, clinical and commercial achievements in the field of biotechnology and life sciences.